Press releaseGlobe Newswire
Alamar Biosciences
ALMR · NASDAQ
$28.16+$1.86 (+7.07%)TodayMarket closed ·
Prev close $26.30
Latest news
- Press releaseGlobe Newswire
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
- NewsAvi Kapoor
Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday
- NewsVandana Singh
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Quantum, Kopin, Alamar Biosciences And Other Big Stocks Moving Higher On Tuesday
- Press releaseGlobe Newswire
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
- Press releaseGlobe Newswire
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
- Press releaseGlobe Newswire
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
- Press releaseGlobe Newswire
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
- Press releaseGlobe Newswire
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
- Press releaseGlobe Newswire
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
- NewsAvi Kapoor
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
- Press releaseGlobe Newswire
Alamar Biosciences Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026
- Press releasePRNewswire
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.